1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015" provides an overview of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) clinical trials scenario. This report provides top line data relating to the clinical trials on Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Clinical Trials by G7 Countries: Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) 22
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Bluebird bio, Inc. 30
Clinical Trial Overview of Bluebird bio, Inc. 30
Aldagen, Inc. (Inactive) 31
Clinical Trial Overview of Aldagen, Inc. (Inactive) 31
NUVISAN GmbH 32
Clinical Trial Overview of NUVISAN GmbH 32
Nutra Pharma Corporation 33
Clinical Trial Overview of Nutra Pharma Corporation 33
Nuo Therapeutics, Inc. 34
Clinical Trial Overview of Nuo Therapeutics, Inc. 34
Neuralgene 35
Clinical Trial Overview of Neuralgene 35
Marcus Foundation Inc 36
Clinical Trial Overview of Marcus Foundation Inc 36
Fate Therapeutics, Inc. 37
Clinical Trial Overview of Fate Therapeutics, Inc. 37
Celgene Corporation 38
Clinical Trial Overview of Celgene Corporation 38
Asklepion Pharmaceuticals, LLC 39
Clinical Trial Overview of Asklepion Pharmaceuticals, LLC 39
Clinical Trial Overview of Top Institutes / Government 40
Duke University 40
Clinical Trial Overview of Duke University 40
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. 41
Clinical Trial Overview of Hugo W. Moser Research Institute at Kennedy Krieger, Inc. 41
Academic Medical Center 42
Clinical Trial Overview of Academic Medical Center 42
Far Eastern Memorial Hospital 43
Clinical Trial Overview of Far Eastern Memorial Hospital 43
FDA Office of Orphan Products Development 44
Clinical Trial Overview of FDA Office of Orphan Products Development 44
Herbert Irving Comprehensive Cancer Center 45
Clinical Trial Overview of Herbert Irving Comprehensive Cancer Center 45
Institute of Biomedical Investigations of Bellvitge 46
Clinical Trial Overview of Institute of Biomedical Investigations of Bellvitge 46
Masonic Cancer Center 47
Clinical Trial Overview of Masonic Cancer Center 47
Five Key Clinical Profiles 48
Appendix 67
Abbreviations 67
Definitions 67
Research Methodology 68
Secondary Research 68
About GlobalData 69
Contact Us 69
Disclaimer 69
Source 70

List of Tables
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Region, 2015* 8
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 11
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Europe, Top Countries, 2015* 12
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, North America, Top Countries, 2015* 13
Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015* 14
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, E7 Countries (%), 2015* 17
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Phase, 2015* 18
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 19
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 20
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 21
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Suspended Clinical Trials, 2015* 22
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Withdrawn Clinical Trials, 2015* 23
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Terminated Clinical Trials, 2015* 24
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bluebird bio, Inc., 2015* 30
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Aldagen, Inc. (Inactive), 2015* 31
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by NUVISAN GmbH, 2015* 32
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nutra Pharma Corporation, 2015* 33
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nuo Therapeutics, Inc., 2015* 34
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Neuralgene, 2015* 35
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Marcus Foundation Inc, 2015* 36
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fate Therapeutics, Inc., 2015* 37
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2015* 38
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Asklepion Pharmaceuticals, LLC, 2015* 39
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2015* 40
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hugo W. Moser Research Institute at Kennedy Krieger, Inc., 2015* 41
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Academic Medical Center, 2015* 42
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Far Eastern Memorial Hospital, 2015* 43
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by FDA Office of Orphan Products Development, 2015* 44
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Herbert Irving Comprehensive Cancer Center, 2015* 45
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Institute of Biomedical Investigations of Bellvitge, 2015* 46
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2015* 47

List of Figures
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Region (%), 2015* 8
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Europe, Top Countries (%), 2015* 12
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 13
Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015* 14
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, E7 Countries (%), 2015* 17
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 18
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 19
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 20
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 21
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 26
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
GlobalData Methodology 68

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Epilepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.